Skip to content

DR. FISCHER

Active
Public limited companyfounded 200125 years activeKBO/BCE: BE 0474.833.905
Summary

The computed 12-month bankruptcy probability of DR. FISCHER is 2.5% (moderate). The 2025 annual accounts show negative equity (-€149,327) and a net result of -€6,254. Equity is shrinking by ~3.4% per year across the filed fiscal years. The company has been active since 2001 and the Belgian State Gazette contains no insolvency signals. The CBE does carry 1 administrative register entry (see administrative flags).

Overview

Activity
Activity not known1 site
Size
€720total assets 2025
Equity
-€149,327
Loss
-€6,254
Financial health
50 Fair Checked score 2025
Bankruptcy probability, 12 months
2.5%
Structure
Parent
Fischer Pharmaceuticals LTD · 100%
Board
1 member
Accounts 2 days early1 of 9 deeds read
Why 50- Loss of €6,254, the second in a row (FY 2025)- Negative equity -€149,327- Ex-officio strike-off in the KBO+ Size: total assets €720Show the evidence

Checked score

Score 2025
50 / 100
Fair
Probability in this band: 1.5% to 4.2%
Financially better than 10% of its sector peers (no NACE code, micro)
Financial strength · tick = 2024
Weak
Solvency 0=
equity -20739.9% of total assets
Liquidity 0=
short-term debt 20839.9%
Profitability 0=
return on assets -868.6%
Bankruptcy probability, 12 months
2.5% Moderate
0%0.5%1.5%4%10%≥ 25%

About 3 in 100 comparable companies go bankrupt within 12 months (an estimate).

Last 24 months 11-2024: 3.8% 12-2024: 3.8%● unchanged vs 11-2024 01-2025: 3.8%● unchanged vs 12-2024 02-2025: 3.8%● unchanged vs 01-2025 03-2025: 3.9%▲ +0.1 percentage points vs 02-2025 04-2025: 3.9%● unchanged vs 03-2025 05-2025: 3.9%● unchanged vs 04-2025 06-2025: 4.3%▲ +0.4 percentage points vs 05-2025highest value 07-2025: 2.9%▼ -1.4 percentage points vs 06-2025 08-2025: 2.9%● unchanged vs 07-2025 09-2025: 2.9%● unchanged vs 08-2025 10-2025: 2.9%● unchanged vs 09-2025 11-2025: 2.9%● unchanged vs 10-2025 12-2025: 2.9%● unchanged vs 11-2025 01-2026: 2.9%● unchanged vs 12-2025 02-2026: 2.5%▼ -0.4 percentage points vs 01-2026 03-2026: 2.7%▲ +0.2 percentage points vs 02-2026 04-2026: 2.7%● unchanged vs 03-2026 05-2026: 2.6%▼ -0.1 percentage points vs 04-2026 06-2026: 3.0%▲ +0.4 percentage points vs 05-2026 07-2026: 3.2%▲ +0.2 percentage points vs 06-2026 08-2026: 2.5%▼ -0.7 percentage points vs 07-2026lowest value 09-2026: 2.5%● unchanged vs 08-2026lowest value 10-2026: 2.5%● unchanged vs 09-2026lowest value
No credit on open account
equity is negative.
How it is calculated

The band follows from the bankruptcy probability, on a scale where 10 more points roughly halve it:

75-100 Excellent under 0.55%
60-74 Healthy 0.55% to 1.5%
45-59 Fair 1.5% to 4.2%
25-44 Weak 4.2% to 15.0%
0-24 Critical over 15.0%

Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (no NACE code, micro): better than 5% on solvency, 1% on liquidity, 4% on profitability and 32% on growth.

The bankruptcy probability was computed on 06-10-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.

Some facts cap the score, however low the probability. Negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late hold it at Fair at most (59); two missing filings, at Weak (44). An ongoing judicial reorganisation or the company's end (bankruptcy, dissolution, liquidation) holds it at Critical at most (24).

Credit check for your own amount and term

Show the recommended maximum : and see how the verdict changes with amount, term and advance.

Signals

Seven signals.
−lowers risk+raises risk○neutral
lowers risk · Size: total assets €720
The company's size counts in the probability; how much depends on the rest of its profile.
NBB · annual accounts
raises risk · Loss of €6,254, the second in a row (FY 2025)
NBB · annual accounts
raises risk · Negative equity -€149,327
NBB · annual accounts
raises risk · Ex-officio strike-off in the KBO
KBO publications
raises risk · Negative equity
The 2025 annual accounts show negative equity and a net loss.
NBB · annual accounts 2025
Equity per financial year
1819202122232425
2018 to 2025 · latest year -€149,327
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 29-07-2026, 2 days ahead of the deadline.
NBB · 10 filings
Deviation from the deadline
2025
2 days early
2024
34 days early
2023
29 days late
2022
21 days late
2021
77 days late
2020
123 days early
2019
54 days late
← before the deadline after the deadline →
tick = median of all Belgian filings

This company filed its last 7 accounts on average 3 days after the deadline; the Belgian median for financial year 2024 is 4 days before the deadline, and 38% of all filings were late.

raises risk · Administrative warnings in the KBO publications
1 publication by the FPS Economy about this company, such as a strike-off for address, accounts or UBO, or its withdrawal.
KBO publications
Publications
Address struck
Checked, nothing found (1)
neutral · The next deadline is still running
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. Usually files around 21 August (4 of the last 5 filed years within 55 days of that day).
Companies Code · seven months
Position in the running window
07-10-2026 today31-12-2026 close31-07-2027 deadline
  1. Reappointment: Eliezer Fischer (director)Appointment: Eliezer Fischer (managing director)…
  2. Annual accounts filedfiscal year 2025 · full…
  3. Weakest financial yearnet -€6,254

Key points

  • Risk: Negative equityfiscal year 2025: debts exceed assets -€149,327 View
  • Risk: 8 loss-making years in a rowloss fiscal year 2025 -€6,254 View
  • Controlled by Fischer Pharmaceuticals LTDknown shareholders 100% 100% View

By topic

Financials

Fiscal year
2025
Total assets
€720
Loss
-€6,254
Solvency
-20739.9%
Total assets=
Net result
20182025
Go to Financials

Board & ownership

Board
1 member
Parent
Fischer Pharmaceuticals LTD · 100%
Known shareholders
100%
Go to Board & ownership

Timeline

Events
13
Since
2017
Next accounts
by 31-07-2027
  1. 27-06-2025Annual accounts filed
  2. 29-08-2024Annual accounts filed
  3. 12-01-2024Address struck
Go to Timeline

Company details

Sites
1
Legal form
Public limited company
Founded
18-05-2001
Year ends
31-12
Peppol
Not found in the Peppol directory
Go to Company details

Go further with this company

Your own company? See how customers, suppliers and banks see it and what to improve first.

Investigating this company? Keep it with today's facts in a case file.